Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Files Polatuzumab Vedotin for DLBCL in Japan
July 1, 2020
- Otsuka, Axcelead Link Up for Drug Discovery in CNS Field
July 1, 2020
- Nichi-Iko to Suspend Supply of Olmesartan OD Tab. 20 mg as COVID-19 Cripples API Procurement
July 1, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
- Sanofi Launches Japan’s 1st Humalog Biosimilar
June 30, 2020
- EU Advisory Panel Snubs Daiichi Sankyo Cancer Med Pexidartinib
June 30, 2020
- Takeda to See US$200 Million Operating Loss Tied to Novartis' EU Xiidra Withdrawal
June 30, 2020
- Mitsubishi Tanabe Files Inebilizumab in Japan for NMOSD
June 29, 2020
- Pfizer Japan Boosting Biosimilar Sales Structure with Dedicated Unit, Ups Its Quality Pitch
June 29, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
- Eisai’s Parkinson’s Med Equfina Gets South Korea Nod
June 26, 2020
- Sosei, AbbVie Link Arms for Inflammatory and Autoimmune Disease Drugs
June 26, 2020
- Carna Biosciences Takes Back Kinase Inhibitor from Canadian Licensee
June 26, 2020
- Japan Sales Rep Promotions in April Tumble 61% YOY: Intage
June 25, 2020
- Takeda’s CEO Pay Tops 2 Billion Yen in FY2019; Old Guard Pitch to Send in External Director Rejected
June 25, 2020
- Orphan Status Granted to Otsuka Gene Therapy, SanBio Cell Program
June 25, 2020
- 7 Authorized Generics in June Listing Target Combined 260 Billion Yen Market; Simultaneous Launches Catching On
June 24, 2020
- Rohto to Launch Stem Cell Clinical Trial for COVID-19 in August, Eyes Conditional OK
June 24, 2020
- Pfizer Japan Draws Up Post-COVID-19 “New Normal Roadmap,” Easing Voluntary Restrictions in Phases
June 24, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…